NO971899L - Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom - Google Patents
Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdomInfo
- Publication number
- NO971899L NO971899L NO971899A NO971899A NO971899L NO 971899 L NO971899 L NO 971899L NO 971899 A NO971899 A NO 971899A NO 971899 A NO971899 A NO 971899A NO 971899 L NO971899 L NO 971899L
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- alzheimer
- disease
- pct
- acetonitrile
- Prior art date
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- -1 oct-3-yl Chemical group 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 230000007450 amyloidogenic pathway Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000020978 protein processing Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9421472A GB9421472D0 (en) | 1994-10-25 | 1994-10-25 | Novel methods |
| PCT/EP1995/004082 WO1996012486A1 (en) | 1994-10-25 | 1995-10-17 | Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971899D0 NO971899D0 (no) | 1997-04-24 |
| NO971899L true NO971899L (no) | 1997-04-24 |
| NO312055B1 NO312055B1 (no) | 2002-03-11 |
Family
ID=10763350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971899A NO312055B1 (no) | 1994-10-25 | 1997-04-24 | Anvendelse av [R-(Z)]-<alfa>-(metoksyimino)-<alfa>-(1- azabicyklo[2.2.2]okt-3-yl)acetonitril til fremstilling av etmedikament for å redusere amyloid <beta>-A4-dannelse hosAlzheimer's sykdom |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5891887A (no) |
| EP (1) | EP0786998B1 (no) |
| JP (1) | JPH10509697A (no) |
| KR (1) | KR100393365B1 (no) |
| CN (1) | CN1085529C (no) |
| AT (1) | ATE214926T1 (no) |
| AU (1) | AU698695B2 (no) |
| BG (1) | BG101500A (no) |
| BR (1) | BR9509433A (no) |
| CZ (1) | CZ287370B6 (no) |
| DE (1) | DE69526102T2 (no) |
| DK (1) | DK0786998T3 (no) |
| ES (1) | ES2173977T3 (no) |
| GB (1) | GB9421472D0 (no) |
| HU (1) | HUT77007A (no) |
| NO (1) | NO312055B1 (no) |
| NZ (1) | NZ295155A (no) |
| PT (1) | PT786998E (no) |
| SK (1) | SK50497A3 (no) |
| WO (1) | WO1996012486A1 (no) |
| ZA (1) | ZA958946B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU751607B2 (en) * | 1995-07-29 | 2002-08-22 | Smithkline Beecham Plc | Method of treatment of dementia |
| GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
| IL138192A0 (en) | 1998-03-11 | 2001-11-25 | Smithkline Beecham Plc | Controlled release oral dosage forms |
| GB9815383D0 (en) * | 1998-07-15 | 1998-09-16 | Smithkline Beecham Plc | Novel method of treatment |
| US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| US7816149B2 (en) * | 2004-03-29 | 2010-10-19 | Applied Photonics Worldwide, Inc. | Nanobioprocessor for protein and cell therapy |
| GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0392803T3 (da) * | 1989-04-13 | 2004-10-18 | Beecham Group Plc | Hidtil ukendte forbindelser |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| MX9300875A (es) * | 1992-02-20 | 1993-08-31 | Smithkline Beecham Plc | Procedimiento para la preparacion de compuestos azabiciclicos. |
| WO1994009370A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors |
| GB9409705D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
-
1994
- 1994-10-25 GB GB9421472A patent/GB9421472D0/en active Pending
-
1995
- 1995-10-17 DE DE69526102T patent/DE69526102T2/de not_active Expired - Fee Related
- 1995-10-17 PT PT95936515T patent/PT786998E/pt unknown
- 1995-10-17 NZ NZ295155A patent/NZ295155A/en unknown
- 1995-10-17 SK SK504-97A patent/SK50497A3/sk unknown
- 1995-10-17 HU HU9701815A patent/HUT77007A/hu unknown
- 1995-10-17 ES ES95936515T patent/ES2173977T3/es not_active Expired - Lifetime
- 1995-10-17 KR KR1019970702700A patent/KR100393365B1/ko not_active Expired - Fee Related
- 1995-10-17 AU AU38431/95A patent/AU698695B2/en not_active Ceased
- 1995-10-17 EP EP95936515A patent/EP0786998B1/en not_active Expired - Lifetime
- 1995-10-17 CN CN95196837A patent/CN1085529C/zh not_active Expired - Fee Related
- 1995-10-17 DK DK95936515T patent/DK0786998T3/da active
- 1995-10-17 BR BR9509433A patent/BR9509433A/pt not_active Application Discontinuation
- 1995-10-17 CZ CZ19971251A patent/CZ287370B6/cs not_active IP Right Cessation
- 1995-10-17 AT AT95936515T patent/ATE214926T1/de not_active IP Right Cessation
- 1995-10-17 WO PCT/EP1995/004082 patent/WO1996012486A1/en not_active Ceased
- 1995-10-17 JP JP8513628A patent/JPH10509697A/ja not_active Ceased
- 1995-10-17 US US08/836,013 patent/US5891887A/en not_active Expired - Fee Related
- 1995-10-23 ZA ZA958946A patent/ZA958946B/xx unknown
-
1997
- 1997-04-24 NO NO19971899A patent/NO312055B1/no not_active IP Right Cessation
- 1997-05-20 BG BG101500A patent/BG101500A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ287370B6 (en) | 2000-11-15 |
| WO1996012486A1 (en) | 1996-05-02 |
| DK0786998T3 (da) | 2002-07-15 |
| PT786998E (pt) | 2002-09-30 |
| ES2173977T3 (es) | 2002-11-01 |
| BG101500A (en) | 1998-01-30 |
| KR100393365B1 (ko) | 2003-12-18 |
| EP0786998A1 (en) | 1997-08-06 |
| AU698695B2 (en) | 1998-11-05 |
| NO971899D0 (no) | 1997-04-24 |
| MX9703077A (es) | 1997-07-31 |
| CN1170365A (zh) | 1998-01-14 |
| CN1085529C (zh) | 2002-05-29 |
| AU3843195A (en) | 1996-05-15 |
| HK1002057A1 (en) | 1998-07-31 |
| EP0786998B1 (en) | 2002-03-27 |
| ZA958946B (en) | 1996-08-20 |
| CZ125197A3 (en) | 1997-07-16 |
| GB9421472D0 (en) | 1994-12-07 |
| ATE214926T1 (de) | 2002-04-15 |
| BR9509433A (pt) | 1997-09-16 |
| NZ295155A (en) | 2000-07-28 |
| KR970706816A (ko) | 1997-12-01 |
| JPH10509697A (ja) | 1998-09-22 |
| US5891887A (en) | 1999-04-06 |
| DE69526102T2 (de) | 2002-10-31 |
| HUT77007A (hu) | 1998-03-02 |
| SK50497A3 (en) | 1997-09-10 |
| DE69526102D1 (de) | 2002-05-02 |
| NO312055B1 (no) | 2002-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| GR3022459T3 (en) | Quinuclidine derivative as substance p antagonist. | |
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| GB2285219A (en) | Use of norastemizole for the treatment of allergic disorders | |
| GEP20053423B (en) | Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits | |
| ZA974387B (en) | Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases. | |
| NO971899L (no) | Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| BRPI0409387A (pt) | método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| HUP0401798A2 (hu) | Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására | |
| English et al. | Recurrent suppurative thyroiditis due to pyriform fossa—thyroid fistula | |
| ZA933567B (en) | Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease | |
| ECSP003616A (es) | Micofenolato mofetil en asociacion con peg-ifn-alfa | |
| CO5150206A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| YU9302A (sh) | Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa | |
| RU98114985A (ru) | Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |